Total R&D costs including costs of capital for select cancer drugs 2017
This statistic shows the total cost of research and development (R&D) including a 7 percent per annum cost of capital for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost, including capital, of around 1.09 billion U.S. dollars as of 2017. Total R&D costs without the 7 percent of annual cost of capital stood at some 818 million dollars.
